Comparison of procedural, clinical and valve performance results of transcatheter aortic valve replacement in patients with bicuspid versus tricuspid aortic stenosis

Limited date describing the procedural, clinical and valve performance results of transcatheter aortic valve replacement (TAVR) in patients with bicuspid versus tricuspid aortic stenosis (TAV). Procedural and clinical results were defined and reported according to VARC-2 criteria. Consecutive 87 pat...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cardiology 2018-03, Vol.254, p.69-74
Main Authors: Liao, Yan-biao, Li, Yi-jian, Xiong, Tian-yuan, Ou, Yuan-weixiang, Lv, Wen-yu, He, Jia-ling, Li, Yi-Ming, Zhao, Zhen-gang, Wei, Xin, Xu, Yuan-ning, Feng, Yuan, Chen, Mao
Format: Article
Language:English
Subjects:
Bicuspid aortic stenosis
Transcatheter aortic valve replacement
Type-0 bicuspid aortic stenosis
Type-1 bicuspid aortic stenosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Limited date describing the procedural, clinical and valve performance results of transcatheter aortic valve replacement (TAVR) in patients with bicuspid versus tricuspid aortic stenosis (TAV). Procedural and clinical results were defined and reported according to VARC-2 criteria. Consecutive 87 patients with BAV and 70 patients with TAV were included. Compared to patients with TAV, patients with BAV had similar incidence of second valve implantation (14.9% vs 12.9%, p=0.708), more than mild paravalvular leakage (PVL, 40.2% vs 31.9%, p=0.288), permanent pacemaker implantation (PPM, 24.1% vs 28.6%, p=0.53). Furthermore, the procedural and clinical results of TAVR also did not differ between patients with type 0 and type 1 (second valve implantation: 18.4% vs 11.8%, p=0.71, PVL: 38.8% vs 41.2%, p=0.83, PPM: 18.4% vs 31.6%, p=0.16). The hemodynamic outcomes were similar in patients with BAV and TAV at 1-year (maximum velocity, 2.3 vs 2.2m/s, p=0.307) and 2-year (2.3 vs 2.1m/s, p=0.184) follow-up respectively. Adjusted binary logistic regression analysis found oversizing ratio at 14.45–20.57% is at lower risk for more than mild PVL (OR, 0.069, 95% CI, 0.011–0.428, p=0.004). Moreover, the Kaplan–Meier survival analysis revealed that TAVR in type 0 BAV, type 1 BAV and TAV have comparable risk for midterm mortality (Log rank, p=0.772). TAVR in whatever type of BAV appeared to be safe and efficacy, and TAVR in BAV was associated with comparable bioprosthetic function during follow up compared to patients with TAV.
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2017.12.013